Research programme: peptide therapeutics transdermal - Zealand Pharma
Latest Information Update: 16 Apr 2009
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 16 Apr 2009 Investigation in Undefined indication in Denmark (Transdermal)